Altimmune (ALT) Return on Equity (2016 - 2025)

Altimmune (ALT) has disclosed Return on Equity for 15 consecutive years, with 0.01% as the latest value for Q4 2025.

  • Quarterly Return on Equity rose 4.0% to 0.01% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.01% through Dec 2025, up 4.0% year-over-year, with the annual reading at 0.02% for FY2025, 3.0% up from the prior year.
  • Return on Equity for Q4 2025 was 0.01% at Altimmune, down from 0.03% in the prior quarter.
  • The five-year high for Return on Equity was 0.03% in Q3 2025, with the low at 0.49% in Q3 2023.
  • Average Return on Equity over 5 years is 0.17%, with a median of 0.11% recorded in 2022.
  • The sharpest move saw Return on Equity skyrocketed 50bps in 2021, then plummeted -45bps in 2023.
  • Over 5 years, Return on Equity stood at 0.09% in 2021, then plummeted by -380bps to 0.44% in 2022, then surged by 69bps to 0.13% in 2023, then skyrocketed by 61bps to 0.05% in 2024, then skyrocketed by 73bps to 0.01% in 2025.
  • According to Business Quant data, Return on Equity over the past three periods came in at 0.01%, 0.03%, and 0.0% for Q4 2025, Q3 2025, and Q2 2025 respectively.